[1]Pillai RN, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;123:4099-105.
[2]Offin M, et al. Frequency and Outcomes of Brain Metastases in Patients With HER2-Mutant Lung Cancers. Cancer. 2019;125(24):4380-4387.
[3]Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer[J]. N Engl J Med. 2022 Jan 20;386(3):241-251.
[4]苏春霞, 俞昕. 驱动基因突变非小细胞肺癌免疫治疗的研究进展[J]. 肿瘤防治研究, 2023; 50(1): 1-5.
[5]Janne P, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02[J]. Journal of Clinical Oncology, 2024, 42(suppl_16): 8543.
[6]Cheng Y, et al. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial [abstract]. AACR 2024. Abstract CT248.
[7]2024 CSCO 非小细胞肺癌诊疗指南.
[8]2024年V7版《NCCN NSCLC临床实践指南》.
[9]Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
[10]Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1. 2024 WCLC, OA16.05.
[11]喻莹, 范云. HER2突变非小细胞肺癌的治疗:下一个突破点[J]. 循证医学, 2022, 22(4): 193-197.